|
293 Companies |
|
491 Products |
|
491 Products |
|
198 Mechanisms of Action |
|
26 Trials |
|
7805 News |
|
| «12...2122232425262728293031...156157» |
- || DegludecPlus (insulin degludec/insulin aspart) / Novo Nordisk
Trial primary completion date: Post Marketing Surveillance (PMS) Study of Ryzodeg (clinicaltrials.gov) - Jan 9, 2017
P=N/A, N=1000, Enrolling by invitation, Sponsor: Novo Nordisk A/S
Trial primary completion date: Nov 2017 --> May 2017
- ||||| Lupuzor (rigerimod) / ImmuPharma, Alora Pharma
Enrollment closed: A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus (clinicaltrials.gov) - Jan 9, 2017
P3, N=200, Active, not recruiting, Sponsor: ImmuPharma
Trial primary completion date: Nov 2017 --> May 2017 Recruiting --> Active, not recruiting
- New trial: Metabolic Profiling of Type 1 Diabetes Mellitus in Children and Adolescents (clinicaltrials.gov) - Jan 8, 2017
P=N/A, N=14, Completed, Sponsor: Hasselt University
- ||||||| Tysabri (natalizumab) / Biogen, Royalty
Trial completion: Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis (clinicaltrials.gov) - Jan 8, 2017
P3, N=900, Completed, Sponsor: Biogen
Recruiting --> Active, not recruiting No longer recruiting --> Completed
- || Enrollment closed: PAS:IDE: Post-PMA Approval Study: 10 Year Follow-Up IDE Subjects (clinicaltrials.gov) - Jan 6, 2017
P=N/A, N=350, Active, not recruiting, Sponsor: Corin
No longer recruiting --> Completed Enrolling by invitation --> Active, not recruiting
- Trial termination: A Study to Assess Inflammation in Rheumatoid Arthritis Using Molecular Imaging Techniques (clinicaltrials.gov) - Jan 6, 2017
P1, N=13, Terminated, Sponsor: GlaxoSmithKline
Enrolling by invitation --> Active, not recruiting Completed --> Terminated; A decision to stop the study was made by the site and GSK project team based on pre-defined stopping criteria in the protocol
- New trial: Changes in Arterial Stiffness and Endothelial Glycocalyx in Patients With Poorly Controlled Diabetes Mellitus Type 1 or Type 2 After Optimization of Antidiabetic Medication. (clinicaltrials.gov) - Jan 5, 2017
P=N/A, N=60, Recruiting, Sponsor: University of Athens
- | Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
Phase classification: REQUEST: A Feasibility Study Exploring the Effect of Remicade on the Disease Activity in RA Patients (Study P05417) (clinicaltrials.gov) - Jan 4, 2017
P4, N=363, Completed, Sponsor: Merck Sharp & Dohme Corp.
Completed --> Terminated; A decision to stop the study was made by the site and GSK project team based on pre-defined stopping criteria in the protocol Phase classification: P=N/A --> P4
- |||| atacicept (VT-001) / Vera Therap
Trial completion: ADDRESS II: Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus (clinicaltrials.gov) - Jan 4, 2017
P2b, N=306, Completed, Sponsor: EMD Serono
Phase classification: P=N/A --> P4 Active, not recruiting --> Completed
- Enrollment open, Trial initiation date, Trial primary completion date: "MS-Fit": Standardized Ambulatory Neurorehabilitation Program for Patients With Multiple Sclerosis (clinicaltrials.gov) - Jan 4, 2017
P=N/A, N=62, Recruiting, Sponsor: University Hospital Inselspital, Berne
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Jul 2015 --> Feb 2016 | Trial primary completion date: Jul 2017 --> Jul 2018
- New trial, HEOR: OHRQoL Evaluation After Functional Therapy in JIA Patients (clinicaltrials.gov) - Jan 4, 2017
P=N/A, N=93, Completed, Sponsor: University of Messina
- Trial primary completion date: Study to Evaluate Immune Responses in Neurologically Normal Cancer Patients (clinicaltrials.gov) - Jan 4, 2017
P=N/A, N=10, Recruiting, Sponsor: Rockefeller University
Not yet recruiting --> Recruiting | Initiation date: Jul 2015 --> Feb 2016 | Trial primary completion date: Jul 2017 --> Jul 2018 Trial primary completion date: Dec 2016 --> Dec 2020
- New trial: AT-thyro: Clinical Application of Pulse Rate-monitoring Activity Trackers in Thyrotoxicosis (clinicaltrials.gov) - Jan 3, 2017
P=N/A, N=40, Recruiting, Sponsor: Seoul National University Bundang Hospital
- Trial primary completion date: Multidimensional Assessment of Fatigue in Multiple Sclerosis- Observational Study - Ticino (clinicaltrials.gov) - Dec 30, 2016
P=N/A, N=100, Recruiting, Sponsor: Claudio Gobbi
Trial primary completion date: Dec 2016 --> Dec 2020 Trial primary completion date: Dec 2016 --> Dec 2017
- ||| Careram (iguratimod) - Eisai, R / Pharm
Trial completion, Enrollment change, Trial primary completion date: Investigation of the Safety and Efficacy of Iguratimod in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Dec 30, 2016
P=N/A, N=2747, Completed, Sponsor: Eisai Co., Ltd.
Trial primary completion date: Dec 2016 --> Dec 2017 Recruiting --> Completed | N=1108 --> 2747 | Trial primary completion date: Dec 2016 --> Apr 2014
- ||||||| Plivensia (sirukumab) / J&J
Trial completion: A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D) (clinicaltrials.gov) - Dec 30, 2016
P3, N=1670, Completed, Sponsor: Janssen Research & Development, LLC
Recruiting --> Completed | N=1108 --> 2747 | Trial primary completion date: Dec 2016 --> Apr 2014 Active, not recruiting --> Completed
- New trial: Multiple Sclerosis and Pilates (clinicaltrials.gov) - Dec 30, 2016
P=N/A, N=30, Recruiting, Sponsor: University of Saskatchewan
- Biomarker, New trial: Study of Methotrexate Given to Juvenile Idiopathic Arthritis Patients Based on Pharmacogenomics and Pharmacometrics (clinicaltrials.gov) - Dec 30, 2016
P=N/A, N=100, Recruiting, Sponsor: Guangzhou Women and Children's Medical Center
- Solu-Cortef (hydrocortisone sodium succinate injection) / Pfizer
Trial completion, Enrollment change: Continuous Subcutaneous Hydrocortisone Infusion In Addison's Disease and Type 1 Diabetes (clinicaltrials.gov) - Dec 30, 2016
P2, N=2, Completed, Sponsor: Haukeland University Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=10 --> 2
- ||||| Remicade (infliximab) / J&J
New P4 trial: HARIR: Tracking Biologics Along the Silk Road (clinicaltrials.gov) - Dec 30, 2016
P4, N=338, Recruiting, Sponsor: Janssen Pharmaceutica N.V., Belgium
- Trial completion, Trial initiation date: Adrenal Function After Living Kidney Donation (clinicaltrials.gov) - Dec 29, 2016
P=N/A, N=30, Completed, Sponsor: University of Zurich
Active, not recruiting --> Completed | N=10 --> 2 Recruiting --> Completed | Initiation date: Dec 2005 --> Jan 2007
- New trial: Characteristics and Predictors of Progression of an Egyptian Multiple Sclerosis Cohort (clinicaltrials.gov) - Dec 29, 2016
P=N/A, N=1581, Completed, Sponsor: Cairo University
- Leukine (sargramostim) / Partner Therap
Enrollment closed: Pulmonary Alveolar Proteinosis GM-CSF Inhalation Efficacy Trial in Japan (clinicaltrials.gov) - Dec 29, 2016
P2, N=80, Active, not recruiting, Sponsor: Niigata University Medical & Dental Hospital
Recruiting --> Completed | Initiation date: Dec 2005 --> Jan 2007 Recruiting --> Active, not recruiting
- | Leukine (sargramostim) / Partner Therap
Trial completion: SK-1401 (rhGM-CSF Agent for Inhalation) GM-CSF Inhalation Pharmacokinetic Study (clinicaltrials.gov) - Dec 28, 2016
P1, N=14, Completed, Sponsor: Niigata University Medical & Dental Hospital
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- || Tresiba (insulin degludec) / Novo Nordisk
Enrollment closed: A Non-interventional, Post Marketing Surveillance (PMS) Study of Tresiba (clinicaltrials.gov) - Dec 28, 2016
P=N/A, N=1000, Active, not recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Enrolling by invitation --> Active, not recruiting
- |||| andecaliximab (GS-5745) / Gilead
Enrollment open: RA POC: Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis (clinicaltrials.gov) - Dec 27, 2016
P2, N=75, Recruiting, Sponsor: Gilead Sciences
Enrolling by invitation --> Active, not recruiting Not yet recruiting --> Recruiting
- Zostavax (zoster vaccine live) / Merck (MSD)
Enrollment closed, Trial primary completion date: Safety and Effectiveness Study of the Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE) (clinicaltrials.gov) - Dec 27, 2016
P2, N=125, Active, not recruiting, Sponsor: University of Alabama at Birmingham
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Dec 2016
- clopidogrel / Generic mfg.
Trial primary completion date, IO biomarker: CLOPUS: Pilot Study Related to the Effect of Clopidogrel on Plasmatic Soluble CD40 Ligand During Systemic Lupus Erythematous (clinicaltrials.gov) - Dec 23, 2016
P1/2, N=30, Recruiting, Sponsor: University Hospital, Bordeaux
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Dec 2016 Trial primary completion date: Mar 2017 --> Sep 2017
- Trial primary completion date: SOCOG-MS: Study of Social Cognition by Morphological and Functional Imaging in Multiple Sclerosis Patients (clinicaltrials.gov) - Dec 23, 2016
P=N/A, N=35, Recruiting, Sponsor: University Hospital, Bordeaux
Trial primary completion date: Mar 2017 --> Sep 2017 Trial primary completion date: Nov 2016 --> Apr 2017
- |||| Trial primary completion date: Benefit/Risk Evaluation of Insuman Implantable Versus Insuplant Using Medtronic MiniMed Implantable Pump System in Patients With Type 1 Diabetes (clinicaltrials.gov) - Dec 23, 2016
P3, N=458, Active, not recruiting, Sponsor: Sanofi
Trial primary completion date: Nov 2016 --> Apr 2017 Trial primary completion date: Oct 2016 --> Apr 2017
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
Trial primary completion date: Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris (clinicaltrials.gov) - Dec 23, 2016
P3, N=1, Terminated, Sponsor: GlaxoSmithKline
Trial primary completion date: Oct 2016 --> Apr 2017 Trial primary completion date: May 2022 --> Feb 2020
- Proleukin (aldesleukin) / Novartis, Prometheus, Iovance Biotherap
Trial initiation date, Trial primary completion date: ANEMIL: Evaluating the Interest of Interleukine-2 for Patients With Active Warm Hemolytic Anemia Resistant to Conventional Treatment (clinicaltrials.gov) - Dec 23, 2016
P1/2, N=10, Not yet recruiting, Sponsor: University Hospital, Bordeaux
Trial primary completion date: May 2022 --> Feb 2020 Initiation date: Aug 2015 --> Jan 2017 | Trial primary completion date: Aug 2017 --> Jul 2019
- ||| Betaseron (IFN-β-1b) / Bayer
Trial completion, Adherence: BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon (clinicaltrials.gov) - Dec 22, 2016
P=N/A, N=479, Completed, Sponsor: Bayer
Initiation date: Aug 2015 --> Jan 2017 | Trial primary completion date: Aug 2017 --> Jul 2019 Active, not recruiting --> Completed
- ||||||| Cyltezo (adalimumab biosimilar) / Boehringer Ingelheim
Trial completion: VOLTAIRE-RA: BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - Dec 22, 2016
P3, N=647, Completed, Sponsor: Boehringer Ingelheim
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Phase classification: Comparison of Antibody Levels in Children and Adolescents After Initiation of Insulin Therapy by Either Insulin Aspart or Soluble Human Insulin (clinicaltrials.gov) - Dec 22, 2016
P=N/A, N=74, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Phase classification: P3 --> P=N/A
- | Trial completion, Enrollment change, Trial primary completion date: A Study to Assess Inflammation in Rheumatoid Arthritis Using Molecular Imaging Techniques (clinicaltrials.gov) - Dec 22, 2016
P1, N=13, Completed, Sponsor: GlaxoSmithKline
Phase classification: P3 --> P=N/A Recruiting --> Completed | N=20 --> 13 | Trial primary completion date: Oct 2016 --> Jun 2016
- vatelizumab (GBR 500) / Glenmark
Trial primary completion date: Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839 (clinicaltrials.gov) - Dec 21, 2016
P2, N=62, Terminated, Sponsor: Genzyme, a Sanofi Company
Recruiting --> Completed | N=20 --> 13 | Trial primary completion date: Oct 2016 --> Jun 2016 Trial primary completion date: Oct 2015 --> Apr 2016
- vatelizumab (GBR 500) / Glenmark
Trial primary completion date: Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (clinicaltrials.gov) - Dec 21, 2016
P2a/2b, N=112, Terminated, Sponsor: Genzyme, a Sanofi Company
Trial primary completion date: Oct 2015 --> Apr 2016 Trial primary completion date: Nov 2015 --> Apr 2016
- dalfampridine / Generic mfg.
Trial primary completion date: Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) (clinicaltrials.gov) - Dec 21, 2016
P2, N=25, Active, not recruiting, Sponsor: Johns Hopkins University
Trial primary completion date: Nov 2015 --> Apr 2016 Trial primary completion date: Jan 2016 --> Nov 2016
- ||||||| NovoLog (insulin aspart) / Novo Nordisk
Trial completion: Safety and Efficacy of NovoLog vs. Humalog in Insulin Pumps in Children and Adolescents (clinicaltrials.gov) - Dec 21, 2016
P3, N=299, Completed, Sponsor: Novo Nordisk A/S
Trial primary completion date: Jan 2016 --> Nov 2016 No longer recruiting --> Completed
- Trial completion: SIGNS: Assessment of Immunoglobulins (IgG) in a Long-term Non-interventional Study (clinicaltrials.gov) - Dec 21, 2016
P=N/A, N=685, Completed, Sponsor: Technische Universit
No longer recruiting --> Completed Recruiting --> Completed
- Trial primary completion date, Metastases: Effect of Structured Nutrition Education in Type 1 Diabetes (clinicaltrials.gov) - Dec 20, 2016
P=N/A, N=216, Active, not recruiting, Sponsor: G
Recruiting --> Completed Trial primary completion date: Nov 2016 --> Jun 2017
- Tavneos (avacopan) / Kissei, Amgen, Otsuka
Trial completion: Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade (clinicaltrials.gov) - Dec 20, 2016
P2, N=5, Completed, Sponsor: ChemoCentryx
Trial primary completion date: Nov 2016 --> Jun 2017 Active, not recruiting --> Completed
- | Trial completion: Bigfoot Biomedical Clinical Research Center (CRC) Trial (clinicaltrials.gov) - Dec 19, 2016
P1, N=20, Completed, Sponsor: Bigfoot Biomedical Inc.
Active, not recruiting --> Completed Recruiting --> Completed
- Enrollment open: Reproducibility of Glucose Fluctuations by Standardized Exercise for Patients With Type 1 Diabetes - a Method Study Based on Continuous Glucose Monitoring (clinicaltrials.gov) - Dec 19, 2016
P=N/A, N=20, Recruiting, Sponsor: Nordsjaellands Hospital
Recruiting --> Completed Not yet recruiting --> Recruiting
- Trial completion: Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis (clinicaltrials.gov) - Dec 15, 2016
P1/2, N=9, Completed, Sponsor: Germans Trias i Pujol Hospital
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || Bimzelx (bimekizumab) / UCB, Cimzia (certolizumab pegol) / Astellas, UCB
Clinical: Multiple Dose Study of UCB4940 as add-on to Certolizumab Pegol in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Dec 15, 2016
P2, N=159, Active, not recruiting, Sponsor: UCB Celltech
Active, not recruiting --> Completed Trial primary completion date: Dec 2016 --> Apr 2017
- || mycophenolate mofetil / Generic mfg.
New P3 trial: PEMPA: Pharmacokinetics Study of Mycophenolic Acid in Patients With an Autoimmune Bullous Dermatose, Pemphigus or Cicatricial Pemphigoid. (clinicaltrials.gov) - Dec 15, 2016
P3, N=60, Not yet recruiting, Sponsor: University Hospital, Limoges
- Trial initiation date: A Single Dose Clinical Trial to Study the Safety of ART-I02 in Patients With Arthritis (clinicaltrials.gov) - Dec 14, 2016
P1, N=15, Not yet recruiting, Sponsor: Arthrogen
Trial primary completion date: Dec 2016 --> Apr 2017 Initiation date: Sep 2016 --> Feb 2017
- || AMG 108 / AstraZeneca
Trial primary completion date: Long-Term Assessment of Safety and Physical Function With AMG 108 in RA (clinicaltrials.gov) - Dec 13, 2016
P2, N=690, Completed, Sponsor: Amgen
Initiation date: Sep 2016 --> Feb 2017 Trial primary completion date: Jan 2009 --> Jun 2008